The HTAC recommends the emergency use of COVID-19 mRNA Vaccine (Nucleoside Modified) (COVID-19 Vaccine Moderna) for the prevention of COVID-19 for persons aged 18 and older.

COVID-19 Vaccine Moderna under Emergency Use

The emergency use authorization of the Food and Drug Administration (FDA) (dated 07 May 2021) allows for timely access of COVID-19 vaccines for Filipinos during the pandemic. This assures the public that the COVID-19 vaccine has passed the quality, safety, and efficacy criteria. Nevertheless, studies are continuing to determine its long-term efficacy and safety and its potential to reduce COVID-19 transmission.

How does COVID-19 Vaccine Moderna work?

The mRNA contained in the vaccine will harness the cellular synthetic mechanism to produce the spike protein that will consequently stimulate the immune system to mount the defense mechanisms against the virus when it infects the person.

Why is COVID-19 Vaccine Moderna recommended by HTAC?

Current available data suggests COVID-19 mRNA Vaccine Vaccine may prevent symptomatic COVID-19 and reduce risk for hospital visits for persons aged 18 and older.

Compared to experience with previous non-COVID vaccines, health authorities worldwide have noted few reported side effects, with no serious injuries or deaths resulting from vaccination.

Based on existing evidence from ongoing trials, the HTAC considers that the vaccine’s positive health impacts outweigh its short-term risks.

Other factors informing the HTAC recommendation include potential health, economic, and social benefits in recommending COVID-19 Vaccine Moderna.

As new information emerges, the Council will continue to update its recommendations and provide our policymakers, health providers, and the Filipino public evidence-based guidance.


Guidance for Health Care Providers:

Evidence summary: